C WorldWide Group Holding A S Sells 450,681 Shares of Edwards Lifesciences Co. (NYSE:EW)

C WorldWide Group Holding A S reduced its holdings in Edwards Lifesciences Co. (NYSE:EW) by 49.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 458,553 shares of the medical research company’s stock after selling 450,681 shares during the period. Edwards Lifesciences makes up about 0.4% of C WorldWide Group Holding A S’s investment portfolio, making the stock its 24th largest position. C WorldWide Group Holding A S’s holdings in Edwards Lifesciences were worth $33,947,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Harbor Capital Advisors Inc. increased its position in Edwards Lifesciences by 2.5% in the 4th quarter. Harbor Capital Advisors Inc. now owns 11,135 shares of the medical research company’s stock worth $824,000 after buying an additional 273 shares during the period. Nordea Investment Management AB increased its position in shares of Edwards Lifesciences by 34.6% during the fourth quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company’s stock valued at $301,355,000 after purchasing an additional 1,043,484 shares during the period. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST increased its position in shares of Edwards Lifesciences by 6.7% during the fourth quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,800,000 shares of the medical research company’s stock valued at $355,344,000 after purchasing an additional 300,000 shares during the period. Sivik Global Healthcare LLC bought a new stake in shares of Edwards Lifesciences during the fourth quarter valued at approximately $3,702,000. Finally, Avanza Fonder AB bought a new stake in shares of Edwards Lifesciences during the fourth quarter valued at approximately $4,845,000. 79.46% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on EW shares. Canaccord Genuity Group boosted their price objective on Edwards Lifesciences from $68.00 to $71.00 and gave the company a “hold” rating in a research report on Thursday, February 13th. The Goldman Sachs Group boosted their price objective on Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, December 5th. Sanford C. Bernstein upgraded Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research report on Monday, October 28th. Wolfe Research lowered Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 12th. Finally, Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and boosted their price target for the company from $82.00 to $90.00 in a research note on Monday, December 16th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $79.95.

Edwards Lifesciences Trading Down 2.0 %

Shares of EW opened at $73.25 on Monday. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12. The firm has a market capitalization of $43.20 billion, a PE ratio of 10.51, a price-to-earnings-growth ratio of 4.82 and a beta of 1.11. The stock’s fifty day simple moving average is $72.85 and its 200-day simple moving average is $70.06.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. As a group, research analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Insider Activity

In related news, VP Daniel J. Lippis sold 2,500 shares of the company’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $74.08, for a total value of $185,200.00. Following the completion of the sale, the vice president now owns 23,189 shares in the company, valued at approximately $1,717,841.12. This represents a 9.73 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Donald E. Bobo, Jr. sold 6,500 shares of the company’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $75.75, for a total value of $492,375.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,555,402. This represents a 12.16 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 26,489 shares of company stock valued at $2,002,829 over the last 90 days. 1.29% of the stock is owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.